Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from Brazil’s National Health Surveillance Agency, ANVISA, for its biosimilars manufacturing facility in Hyderabad.The approval follows a good manufacturing practice inspection conducted by ANVISA from May 11 to May 15, 2026, covering biological active pharmaceutical ingredients and sterile products, Aurobindo Pharma said in a regulatory filing on Tuesday.The inspection scope included four biosimilar products and assessed the company’s mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, and quality control testing and release laboratories.CuraTeQ’s drug substance and drug product GMP facility is already certified by the European Medicines Agency (EMA) and the World Health Organization. The ANVISA approval further supports the company’s regulatory compliance profile and quality standards, the company said.The clearance is expected to strengthen CuraTeQ Biologics’ ability to supply biosimilar products to Brazil and the wider Latin American market, it added.
